SOHO 2022 | OPTIC post hoc analyses: OPTIC and PACE comparison & impact of mutations on ponatinib starting dose

Jorge Cortes • 29 Sep 2022

SOHO 2022

Jorge Cortes, MD, Augusta University, Augusta, GA, comments on some of the results of post-hoc analyses of the OPTIC trial (NCT02467270) which evaluated a response-based dosing regimen of ponatinib in patients with resistant or intolerant chronic myeloid leukemia in the chronic phase (CP-CML). A post-hoc analysis comparing the OPTIC study with the PACE study (NCT01207440) showed that dose adjustments led to a decrease in the incidence of arterial occlusive events without impacting treatment efficacy. In addition, another study demonstrated that patients with specific mutations may respond better to a 45 mg starting dose instead of 30 mg. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.